ConductScience.org, home

Paper36484103

m6 A Reader YTHDF1-Targeting Engineered Small Extracellular Vesicles for Gastric Cancer Therapy via Epigenetic and Immune Regulation.

You Q and 10 others. Adv Mater, 2023. Cited by 88 papers, by iCite.

Cite this record

ConductScience Library. m6 A Reader YTHDF1-Targeting Engineered Small Extracellular Vesicles for Gastric Cancer Therapy via Epigenetic and Immune Regulation. Papers, record 36484103. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36484103

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
m6 A Reader YTHDF1-Targeting Engineered Small Extracellular Vesicles for Gastric Cancer Therapy via Epigenetic and Immune Regulation.
PubMed
Journal
Adv Mater
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
88
iCite
Relative citation ratio, by iCite
7.23
iCite
Revised in PubMed
2023-02-27
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1You QQing
2Wang FFang
3Du RRong
4Pi JJingnan
5Wang HHuayi
6Huo YYue
7Liu JJingyi
8Wang CChen
9Yu JJia
10Yang YYanlian
11Zhu LLinghttps://orcid.org/0000-0003-3818-6093

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Stomach NeoplasmsMajor topic
Extracellular VesiclesMajor topic
Humans
CD47 Antigen
Immunotherapy
Epigenesis, Genetic
RNA-Binding Proteins

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
31971295National Natural Science Foundation of ChinaPubMed
2021YFA1201500National Key Research and Development Program of ChinaPubMed
XDB36000000The Strategic Priority Research Program of Chinese Academy of SciencePubMed

Source PubMed

Download CSV of grants

Cited by63

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 88 citations.

PMIDTitleJournalYearIn PapersSource
42756925m6A-Targeted Cancer Therapy: Molecular Targets, Inhibitors, and Nanodelivery Strategies.Int J Nanomedicine2026https://conductscience.org/library/papers/42756925PubMed
42534149m6A methylation regulatory network in pulmonary fibrosis: Molecular mechanisms from RNA stability to cellular phenotype transition (Review).Exp Ther Med2026https://conductscience.org/library/papers/42534149PubMed
42427965Advancements in extracellular vesicle research.Extracell Vesicle2026https://conductscience.org/library/papers/42427965PubMed
42164998Hit the bull's eye: Engineered extracellular vesicles for targeted therapy.Bioact Mater2026https://conductscience.org/library/papers/42164998PubMed
42077735Global Research Trends in Gastric Cancer Epigenetics From 2005 to 2025.Cureus2026https://conductscience.org/library/papers/42077735PubMed
42072692Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.Biomolecules2026https://conductscience.org/library/papers/42072692PubMed
42056258YTHDF1/SLC39A4 signaling axis promotes gastric cancer cell proliferation by suppressing cuproptosis ex vivo and in vitro.Cancer Gene Ther2026https://conductscience.org/library/papers/42056258PubMed
41992985RNA‑binding proteins as epithelial transcriptome orchestrators in gastric cancer: Immune‑metabolic crosstalk and therapeutic vulnerability (Review).Int J Mol Med2026https://conductscience.org/library/papers/41992985PubMed
41904346The m6A-circRNA axis: a therapeutic prospect for gastric cancer.Cell Biol Toxicol2026https://conductscience.org/library/papers/41904346PubMed
41832397RNA m6A modification is a driver and therapeutic target in gastric cancer.Cell Biol Toxicol2026https://conductscience.org/library/papers/41832397PubMed
41809263Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress.Asian J Pharm Sci2025https://conductscience.org/library/papers/41809263PubMed
41629530RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia.EMBO J2026https://conductscience.org/library/papers/41629530PubMed
41607610The epitranscriptome meets non-coding RNA: m6A-mediated regulation in oncogenesis and therapy.Front Cell Dev Biol2025https://conductscience.org/library/papers/41607610PubMed
41597006Untargeted Metabolomics Reveals Raw Material Geographic Origin as a Key Factor Shaping the Quality of Ginger-Derived Exosome-like Nanovesicles.Foods2026https://conductscience.org/library/papers/41597006PubMed
41522350Targeting the HSP60/p53 Axis with Extracellular Vesicle-Delivered siRNA Reprograms Glycolysis in Prostate Cancer.Int J Biol Sci2026https://conductscience.org/library/papers/41522350PubMed
41457218RNA modifications: roles in immune cell biology and tumor regulation.Cancer Cell Int2025https://conductscience.org/library/papers/41457218PubMed
41423606The crosstalk of m6A modification and non-coding RNAs in gastric cancer: biomarkers and therapeutic potentials.Cancer Cell Int2025https://conductscience.org/library/papers/41423606PubMed
41404378Advancing Epigenetic Combination Therapy in Oncology: Multifunctional Nano-Drug Delivery Systems for Synergistic Efficacy and Precision Modulation.Int J Nanomedicine2025https://conductscience.org/library/papers/41404378PubMed
41022614[Therapeutic potential of extracellular vesicles in neurological diseases].Nan Fang Yi Ke Da Xue Xue Bao2025https://conductscience.org/library/papers/41022614PubMed
40958857Interactions between ALKBH5 and reader proteins in tumors: functions and molecular mechanisms.Front Oncol2025https://conductscience.org/library/papers/40958857PubMed

See all 63 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36484103

GET https://conductscience.org/api/papers/v1/36484103/cited_by?page=2